Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Clinical trial NCT04989322 · UNKNOWN

Trial details

NCT number: NCT04989322
Sponsor: Dr Joanne CHIU
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Nsclc EGFR Activating Mutation EGF-R Positive Non-Small Cell Lung Cancer ALK Gene Rearrangement Positive ROS1 Gene Rearrangement ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Start date: 2021-10-05
Primary completion: 2024-08-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.